Q-omics provides the consensus-scored MIR548I1 profile across patient tissues and cancer cell-line models. MIR548I1 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, MIR548I1 is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, MIR548I1 RNA expression shows 11,172 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCEC, LUSC, and THYM as cancer lineages where MIR548I1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR548I1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR548I1 survival associations across molecular data types. MIR548I1 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR548I1 RNA expression–survival associations across cancer types. High MIR548I1 expression shows unfavorable associations in UCEC, THCA, BRCA, BLCA, UVM and LUSC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for MIR548I1 RNA expression.
This table summarizes MIR548I1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR548I1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR548I1 shows lower tumor expression in LUSC, COAD, BRCA, LUAD and KICH. The LUSC box plot shows higher MIR548I1 RNA expression in normal versus tumor tissue (log2 FC = −0.222, t-test p = .004).
This table shows molecular features associated with MIR548I1 in patient tissues and cancer cell lines. In patient samples, MIR548I1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
